Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
Nyxol
APX3330
APX2009
Posters and Publications
Clinical Trials
Overview
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Recruiting Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Recruiting
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Recruiting Completed
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Recruiting
Partnerships
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
View Ocuphire’s Recent Positive Phase 2 VEGA-1 Topline Data for Presbyopia
View Press Release
Continue
Contact a Trial Coordinator
Clinical Trials
Clinical Trials
Overview
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Contact a Trial Coordinator for more information on our trials.
First Name
Last Name
Email
Clinical Trial
Select a trial
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Comments:
Submit
